15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
"15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A stable prostaglandin endoperoxide analog which serves as a thromboxane mimetic. Its actions include mimicking the hydro-osmotic effect of VASOPRESSIN and activation of TYPE C PHOSPHOLIPASES. (From J Pharmacol Exp Ther 1983;224(1): 108-117; Biochem J 1984;222(1):103-110)
MeSH Number(s)
D02.737.637.650.500.500
D10.251.355.255.100.637.025.650.500.500
D10.251.355.255.550.025.650.500.500
D23.469.050.175.725.720.720.500.500
D23.469.700.630.500
Concept/Terms
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
- 9,11-Dideoxy-11 alpha,9-alpha-epoxymethano-PGF2 alpha
- 9,11-epoxymethano-PGH2
- 9,11 epoxymethano PGH2
- 11 alpha,9 alpha-Epoxymethano PGH2
- 11 alpha,9 alpha Epoxymethano PGH2
- (15S)hydroxy-9alpha,11alpha-(epoxymethano)prosta-5,13-dienoic acid
- (15S)-Hydroxy-11 alpha, 9 alpha-(epoxymethano)prosta-5Z, 13E-dienoic Acid
- 9,11-Dideoxy-11 alpha,9 alpha-epoxymethanoprostaglandin F2 alpha
U-44619- U-44619
- U 44619
- U46619
- U44619
- U-46619
- U 46619
Below are MeSH descriptors whose meaning is more general than "15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid".
- Chemicals and Drugs [D]
- Organic Chemicals [D02]
- Peroxides [D02.737]
- Prostaglandin Endoperoxides [D02.737.637]
- Prostaglandins H [D02.737.637.650]
- Prostaglandin H2 [D02.737.637.650.500]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D02.737.637.650.500.500]
- Lipids [D10]
- Fatty Acids [D10.251]
- Fatty Acids, Unsaturated [D10.251.355]
- Eicosanoids [D10.251.355.255]
- Arachidonic Acids [D10.251.355.255.100]
- Prostaglandins [D10.251.355.255.100.637]
- Prostaglandin Endoperoxides [D10.251.355.255.100.637.025]
- Prostaglandins H [D10.251.355.255.100.637.025.650]
- Prostaglandin H2 [D10.251.355.255.100.637.025.650.500]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D10.251.355.255.100.637.025.650.500.500]
- Prostaglandins [D10.251.355.255.550]
- Prostaglandin Endoperoxides [D10.251.355.255.550.025]
- Prostaglandins H [D10.251.355.255.550.025.650]
- Prostaglandin H2 [D10.251.355.255.550.025.650.500]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D10.251.355.255.550.025.650.500.500]
- Biological Factors [D23]
- Inflammation Mediators [D23.469]
- Autacoids [D23.469.050]
- Eicosanoids [D23.469.050.175]
- Prostaglandins [D23.469.050.175.725]
- Prostaglandin Endoperoxides [D23.469.050.175.725.720]
- Prostaglandins H [D23.469.050.175.725.720.720]
- Prostaglandin H2 [D23.469.050.175.725.720.720.500]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D23.469.050.175.725.720.720.500.500]
- Prostaglandins, Synthetic [D23.469.700]
- Prostaglandin Endoperoxides, Synthetic [D23.469.700.630]
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid [D23.469.700.630.500]
Below are MeSH descriptors whose meaning is more specific than "15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid".
This graph shows the total number of publications written about "15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid" by people in Harvard Catalyst Profiles by year, and whether "15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 6 | 6 |
| 1995 | 0 | 5 | 5 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 3 | 3 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
Below are the most recent publications written about "15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid" by people in Profiles.
-
Increased Coronary Contraction to Thromboxane A2 in Cardiac Surgery Patients With Poorly Controlled Hypertension. J Surg Res. 2024 Feb; 294:249-256.
-
Calcitonin Gene Related Peptide, Adrenomedullin, and Adrenomedullin 2 Function in Uterine Artery During Human Pregnancy. Endocrinology. 2022 01 01; 163(1).
-
Resolvin D1 Enhances Necroptotic Cell Clearance Through Promoting Macrophage Fatty Acid Oxidation and Oxidative Phosphorylation. Arterioscler Thromb Vasc Biol. 2021 03; 41(3):1062-1075.
-
Intratracheal injection of nitric oxide, generated from air by pulsed electrical discharge, for the treatment of pulmonary hypertension in awake ambulatory lambs. Nitric Oxide. 2020 04 01; 97:11-15.
-
Two novel, putative mechanisms of action for citalopram-induced platelet inhibition. Sci Rep. 2018 11 12; 8(1):16677.
-
Contractile protein expression is upregulated by reactive oxygen species in aorta of Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol. 2014 Jan 15; 306(2):H214-24.
-
Altered expression and activation of mitogen-activated protein kinases in diabetic heart during cardioplegic arrest and cardiopulmonary bypass. Surgery. 2013 Sep; 154(3):436-43.
-
Chorionic plate arterial function is altered in maternal obesity. Placenta. 2013 Mar; 34(3):281-7.
-
Hemoglobin infusion does not alter murine pulmonary vascular tone. Nitric Oxide. 2013 Apr 01; 30:1-8.
-
Changes in microvascular reactivity after cardiopulmonary bypass in patients with poorly controlled versus controlled diabetes. Circulation. 2012 Sep 11; 126(11 Suppl 1):S73-80.